Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes of ventricular arrhythmia within 24 hours and associated with a significantly increased mortality and massive health resource utilization. Several therapies are utilized including sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs, implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter ablation. Despite standard intervention, mortality rates remain high and additional therapeutic options are actively being investigated. The overall objective of this proposal is to investigate whether transcutaneous magnetic stimulation designed to inhibit the left stellate ganglion can be used in this population. This is a single-center, randomized, sham-controlled trial to assess the efficacy of transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with ventricular tachycardia storm.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
26
Transcutaneous magnetic stimulation targeting the left stellate ganglion.
Sham transcutaneous magnetic stimulation.
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring
Incidence of ventricular tachycardia on inpatient telemetry monitoring
Time frame: 24-hours following completion of the protocol
Cardioversion - Incidence of ICD Therapies or External Defibrillation Following Stimulation on Device Interrogation or Telemetry
Incidence of ICD or external defibrillation following stimulation on device interrogation or telemetry
Time frame: 48-hours following completion of the protocol
Number of Patients With Changes in ICD or Pacemaker Lead Impedances
Number of patients with changes in lead impedance (unit: Ohms) on device interrogation
Time frame: Immediately following completion of the protocol
Number of Patients With Changes in ICD or Pacemaker Lead Thresholds
Number of patients with changes in lead thresholds (unit: mV) on device interrogation
Time frame: Immediately following completion of the protocol
Number of Patient With Changes in ICD or Pacemaker Lead Sensitivities
Number of patient with changes in lead sensitivity (unit: mA) on device interrogation
Time frame: Immediately following completion of the protocol
Local Effect From Stimulation - Patient Reported Local Discomfort on Visual Analog Scale (0-10)
Scores on a visual analog scale (0-10) of discomfort - 0= no discomfort, 1 = minimal discomfort, 10 = most severe discomfort imaginable.
Time frame: Immediately following completion of the protocol
Antiarrhythmic Drugs Used Post Stimulation - Incidence of Antiarrhythmic Drug Use Post Stimulation Per Inpatient Medical Record
Incidence of antiarrhythmic drug use post stimulation per inpatient medical record
Time frame: 24 hours following completion of the protocol
Number of Patients With Changes in ECG Parameters
Number of patients with any clinical significant change in PR, QRS, or QT interval before and after stimulation.
Time frame: Immediately following completion of the stimulation
Number of Patients With Changes in Vital Signs
Number of patients with clinical significant change in heart rate or blood pressure during the procedure.
Time frame: Immediately following the completion of the stimulation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.